Review our original research from global conferences



4th Annual Tumor Models Conference, Boston

A Panel of Well-Characterized Syngeneic Models for MuScreen™ In Vivo Screening

ADA 76th Scientific Sessions, New Orleans

79-LB: The Use of Dexcom G4 Continuous Glucose Monitoring in Diabetes NHP Research

308-LB: Characterization of FATZO Mice for Diabetes and Obesity Research

911-P: Advantages of Glucose Monitoring with an Implantable Telemetry Device in Freely Moving, Conscious Non-Human Primates

1822-P: Hepatic Lipidosis and Fibrosis in Obese, Dysmetabolic, and Diabetic Non-Human Primates Quantified by Noninvasive Sonography

AACR Annual Meeting, New Orleans

747: Autocrine c-Met/HGF HCC PDX: Evaluation of a Biologic Targeting c-Met

3219: Immunization is Critical to PD-1/PD- L1 Response in a Mouse Breast Cancer Allograft

3994: Immunology Syngeneic Models Demonstrate Additive Effects of Combination Strategies using Checkpoint Immunotherapy and Inducers of Immunogenic Cell Death (ICD)

4043: A Novel Mouse Skin Squamous Cell Carcinoma Allograft Model for In Vivo Pharmacological Analysis of Immunotherapy

4997: Novel Anti-PD- L1/IL-15 Bifunctional Immunotherapeutics Potentiates Antitumor Immunity

5176: Orthotopic Syngeneic Tumor Models for Preclinical Evaluation of Cancer Immunotherapy Strategies

5177: RNAseq and FACS Profiling of Syngeneic Mouse Models Treated with Immune Checkpoint Inhibitors enable Biomarker Discovery and Model Selection for Cancer Immunotherapy

5179: Development of a Humanized Mouse Model for Direct Evaluation of Anti-Human PD-L1 Antibodies

5186: Using HuTrial™ to Aid in Predicting a Patient Population of Responders

6444: MiXeno™ Humanized Mouse Model as an Efficient Tool to Evaluate In Vivo Activity of Anti-Cancer Immunotherapeutics

ENDO 2016, Boston

SUN 720: Blood Glucose Fluctuations during Daily Activities and Stress Procedures in Cynomolgus Monkeys Monitored By Implanted Telemetry Device


AACR Annual Meeting, Philadelphia

765: Overcoming Acquired Resistance in NSCLC with Targeted Beam Irradiation in Combination with Targeted Agents

769: In Vivo Response and Molecular Characterization of a Caucasian NSCLC Squamous Cell Carcinoma PDX Sensitive to FGFR Inhibitors

1038: Cell-based Screening Identifies Gene Expression Signature Correlated with Sensitivity to PI3K/mTOR Dual Inhibitor BEZ235

1472: Building a Comprehensive and Fully Annotated Patient Tumor Derived Xenograft (PDX) Library Mirroring Cancer Patient Population

1802: Application of Small Animal Image-Guided Irradiation to Preclinical In Vivo Models such as Patient-Derived Xenografts to Inform on Combination Strategies

1926: Patient-Derived Xenograft Seem to Have Closer Global Expression Profile to that of Patient Tumors of the Corresponding Cancer Types, than the Equivalent Cell Lines Do

2281: Building Mouse Tumor Derived Allografts for Immuno-Oncology Research

3221: A Patient-Derived Xenograft (PDX) Platform for Development of Next Generation KIT Kinase Inhibitors in Imatinib-Resistant Gastrointestinal Tumors (GIST)

3224: Living Tumor Bank and Patient-Derived Xenograft Models: A Powerful Translational Engine for Novel Oncology Therapeutics

3226: Patient-Derived Xenograft (PDX) Models for Triple Negative Breast Cancer (TNBC): A Preclinical Platform for drug discovery

3235: Validation of Anti-Human PD-1 and PD-L1 Antibodies in MiXeno™ Mouse Models

3581: Rapid Conversion to Resistance of a Colon PDX with RET Fusion by Ponatinib Treatment Could Potentially Be Attributed to the Introduction of the Gate Keeper Mutation V804M

4209: Development of Patient-Derived Xenograft Models for Small Cell Lung Cancer as a Preclinical Platform for Drug Development

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston

247: Drug Resistant Murine Tumor Models Facilitate the Development of Next Generation Anticancer Therapeutics

382: Response to Checkpoint Inhibition by GEMM Breast Cancer Allograft

394: Induction of Resistances to Crizotinib in NSCLC Patient-Derived Xenograft Models Upon Treatment

396: Molecular Pathology of Patient Tumors, Patient-Derived Xenografts and Cancer Cell Lines

399: A HuGEMM h/mPD1 Mouse Model for Testing Anti-Human PD-1 Therapeutics

ADA 75th Scientific Sessions, Boston

Dynamic Changes of Betatrophin, Insulin and Glucose during STZ Induction of Diabetes in Rhesus Monkeys

Long-term Continuous Glucose Monitoring in Conscious Stress-free Non-Human Primates with Implanted Telemetry Device

Effects of Anesthesia on Metabolic Responses to Mixed Meal Tolerance Test in Cynomolgus Monkeys

Left Ventricular Diastolic Dysfunction in Diabetic and Dysmetabolic Non-human Primates

ASH Annual Meeting, Orlando

2759: Activating Mutations in MYD88 and CD79B Are Predictive of Response to Ibrutinib in ABC-DLBCL Tumors

CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, New York City

B115: Application of Image-Guided Irradiation to a Preclinical Bioluminescent Syngeneic Metastatic Breast Cancer Model in Combination with Immunotherapy to Inform on Combination Strategies

B117: Profiling of Syngeneic Models by Check Point Inhibitors, RNAseq, and FACS Analysis Enables Better Selection of Models for Immune Targeted Combination Therapy

18th ECCO, Vienna

228: Preclinical Mouse Trials (MCT) to Guide the Human Studies

201: Profiling of Syngeneic Models by Anti-PD-1, PD-L1 and CTLA-4 Immunotherapeutics and RNAseq Analysis Provides Predictive Biomarkers for Cancer Immunotherapy

New Horizons in Cancer Research Conference: Bringing Cancer Discoveries to Patients, Shanghai

A Novel RET TKI Inhibits Growth of Patient-Derived Xenografts with RET Fusion and Overcomes Ponatinib-Induced Resistance

Drug Resistant Murine Tumor Models Facilitate Development of Next Generation Anticancer Therapeutics

Establishment of a Humanized PD-1 Mouse Model for In Vivo Pharmacological Evaluation of Anti-Human PD-1 Antibodies

Establishment of a Mouse Breast Cancer Allograft Model for In Vivo Pharmacological Analysis of Immunotherapy

High Efficacy of a Novel and Specific c-MET TKI in a Cohort of PDXs from Selected NSCLC and HCC Patients

Immunological Characterization: Allograft of Primary Murine Breast Cancer (MuPrime™) versus Murine Breast Cancer Cell-Derived Syngeneic Tumors


AACR Annual Meeting, San Diego

1206: Parameters Influencing Design of Mouse Clinical Trial (HuTrial™)

2054: Patient Relevant Preclinical In Vivo Models Using Image-Guided Small Animal Irradiation for Drug Discovery

2562: Evaluate In Vivo Efficacy of Antitumor Immunotherapeutics Using MiXeno™ Mouse Models

3123: Modeling Anti-Leukemic Therapy by Patient-Derived AML Xenografts with Distinct Phenotypes/Genotypes

3124: Xenograft Models for Development of New Drugs Targeting Fibroblast Growth Factor Receptor (FGFR)

3136: X-MAN™ Isogenic DualXeno™ Models with KRAS Mutation Predicts the Effect of Anti-EGFR Agents

3440: Cell-based Screening Identifies Gene Expression Signature Correlated with Sensitivity to MEK Inhibitor Trametinib

4875: In Vivo and In Vitro Generation and Characterisation of EGFR-TKI Resistance in Patient-Derived Xenograft (PDX) and Cell Line Derived Xenograft (CDX) Models of NSCLC with Activating EGFR Mutations

AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics, Barcelona

Syngeneic Models for Developing Cancer Therapeutics Targeting Immune System

Treatment of Patient-Derived NSCLC Xenograft Preclinical Models Using Image-Guided Small Animal Irradiation

New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures, Shanghai

Development of a Gene Signature for Stratifying Cisplatin Treatment of NSCLC Patients

Induction of Resistance to Targeted Therapies in Patient-Derived Xenograft Models

Patient-Derived AML Xenografts for Drug Evaluation